Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Complete MEDAL Data May Forge Arcoxia Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical data presented by Merck is not qualitatively different from preliminary release of trial results for the COX-2 inhibitor.
Advertisement

Related Content

Use Of Highly Selective NSAID Comparator In Arcoxia Trials Remains Controversial
Use Of Highly Selective NSAID Comparator In Arcoxia Trials Remains Controversial
Merck Seeks Narrowed Arcoxia Indication In Response To “Approvable” Letter
Merck Seeks Narrowed Arcoxia Indication In Response To “Approvable” Letter
Merck’s Vioxx Successor Arcoxia May Be Closer To Market

Topics

Advertisement
UsernamePublicRestriction

Register

PS063359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel